Introduction
The study of primary virus isolates is necessary to understand many aspects of virus-host interactions and specific viral characteristics (1) (2) (3) (4) (5) , but virus isolation/ propagation is extremely challenging for many virus species and strains. An alternative approach involves cloning specific viral genes into expression or viral genomic vectors to assess function. Expression vectors can be used to produce pseudotyped viruses, but they limit studies to specific steps in the virus replication cycle (6) (7) (8) (9) . Cloning into full-length viral genomes followed by a method for direct virus production provides a more flexible virus replication system to study drug sensitivity, phenotypic resistance in patients on drug treatment, fitness, mechanisms of viral replication, and hostvirus interactions (10) (11) (12) .
Viruses such as human immunodeficiency virus type 1 (HIV-1) or hepatitis C virus (HCV) are highly heterogeneous and lack convenient, conserved, or unique restriction enzyme sites for cloning (13) (14) (15) . In the past, molecular analyses of HIV-1 replication involved only a handful of subtype B laboratory strains (e.g., NL4-3, HXB2, Ada, BH10) but these are not representative of the majority of circulating HIV-1 isolates in the infected population. Several studies have now examined possible phenotypic differences among the 10 different HIV-1 subtypes and at least 33 circulating recombinant forms, which can differ by as much as 25% at the nucleotide level (16) (17) (18) (19) (20) . Any differences in viral phenotypes are typically mapped to specific genetic sequences, but this characterization requires the difficult cloning of diverse genetic elements. As a consequence, few groups have performed drug resistance/susceptibility studies or in-depth analyses on replicative fitness using diverse HIV-1 subtypes. Of these, most have relied on restriction enzymebased cloning into an expression vector for gene complementation/pseudotyping rather than cloning into a full-length viral genome.
These studies, even when successful, prove to be time-consuming and often introduce foreign genetic elements.
An alternative method to bacterial cloning involves transfecting a human cell line (e.g., MT4 cells) (i) with a proviral DNA vector with a deletion in a specific gene and (ii) an HIV-1 PCR product derived from a patient isolate in order to replace the deleted gene (10, 13, 14) . Homologous recombination in mammalian cells can then produce a full-length HIV-1 genome and, ultimately, an infectious virus. Although this method is relatively simple, it is also plagued by the poor efficiency of eukaryotic recombination, an inability to recover the cloned genome, a slow outgrowth of recombined virus, and a heavy selection bias for a few randomly generated clones from a swarm of patient HIV-1 sequences.
Recently, we adopted a yeast-based recombination/gap repair technique to shuttle any HIV-1 genetic element into an HIV-1 vector (15) . This technique has several advantages over mammalian recombination Replication studies on human immunodeficiency virus 1 (HIV-1) rely on a few laboratory strains that are divergent from dominant HIV-1 subtypes in the epidemic. Several phenotypic differences between diverse HIV-1 isolates and subtypes could affect vaccine development and treatment, but this research field lacks robust cloning/virus production systems to study drug sensitivity, replication kinetics, or to develop personalized vaccines. Extreme HIV-1 heterogeneity leaves few restriction enzyme sites for bacterial cloning strategies. In this study, we describe an alternative approach that involves direct introduction of any HIV-1 coding regions (e.g., any gene from a patient sample) into an HIV-1 DNA vector using yeast recombination. This technique uses positive and negative selectable markers in yeast and avoids the need for purification and screening of the DNA substrates and cloning products. Replicationcompetent virus is then produced from a modified mammalian 293T packaging cell line transfected with this yeastderived HIV-1 vector. Although HIV-1 served as the prototype, this cloning strategy is now being developed for other diverse virus species such as hepatitis C virus and influenza virus. 
Production of infectious viruses
The pREC_nfl_HIV-1 plasmid [a shuttle ve vecctor containing the near full-length (nfl) HIV genome] (2 μg) was transfected into 293T or 293T cplt cells using the Effectene lipid system according to the manufacturer's protocol (Qiagen, Valencia, CA, USA). Yeast colonies from C-LEU/5-FOA plates were screened for an HIV-1 env insert by PCR amplification using the ENV pREC primer set (see Supplementary Table 1) .
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Supernatants were collected 3 days posttransfection and frozen at -80°C. Transfection supernatant, containing virus in cell-free media, was used to infect U87.CD4. CXCR4 cells. Supernatants were collected every two days starting 3 days post-infection and monitored for reverse transcription (RT) activity using a radioactive assay as previously described (5). Viruses were then titered using limiting dilution series (RT activity readout) and the Reed Muench tissue culture infectious dose 50 (TCID 50 ) method. The protease-reverse transcriptase (PR-RT) coding region or gag or env gene fragments were PCR amplified from HIV-1 proviral DNA extracted from U87.CD4. CCR5 cells infected with different primary isolate viruses, and then recombined into pREC_nfl_HIV-1ΔPR-RT/URA3, Δgag/ URA3, or Δenv/URA3 to generate chimeric pREC_nfl_HIV-1 plasmids containing the corresponding fragments. To generate the EC2, EC28, and EC38 env chimeric viruses, plasma samples were obtained from Ugandan patients following written informed consent. For producing chimeric viruses, 0.8 µg of the resulting vectors were transfected with Lipofectamine 2000 (Invitrogen) into 1.5 × 10 5 293T cplt cells in 24-well plates according to the manufacturer's protocol. A transfection efficiency of 80% was obtained from the same pREC_nfl vector but harboring GFP as a marker. Chimeric HIV-1 viruses were screened for infectivity and to measure TCID 50 by performing a limiting dilution infection of peripheral blood mononuclear cells, U87.CD4.CCR5, and CXCR4 cells. Virus production in these infections was monitored by RT activity in the supernatant.
Additional methods
Production of the cloning vectors and 293T stable cell line, the PCR techniques, and the Western blot methods are described in full detail in the Supplementary Methods online.
Results

Construction of yeast-based HIV-1 shuttle vector
To address issues of high genetic diversity and lack of conserved restriction enzyme sites in HIV-1, a shuttle vector (pREC_nfl_HIV-1), based on the NL4-3 viral genome, was designed ( Figure 1A, Supplementary Figure  1) . The purpose of this vector is to serve as a www.invitrogen.com
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Validation and optimization of the complementation system
To test our complementation system, supernatants and cells were collected from 293T cultures two days after transfection with pREC_nfl_HIV-1 and/ or pCMV_cplt. The cplt RNA and nfl_ HIV-1 RNA were reverse-transcribed with specific primers and then subjected to real-time PCR to detect a cplt-specific "tag" sequence and the pol region, respectively. Figure 1C shows that when the pREC_nfl_HIV-1 plasmid or pNL4-3 plasmid (positive control consisting of the full length proviral genome) was transfected into 293T cells in the absence of pCMV_cplt, only pol gene RNA could be amplified above background. Likewise, when pCMV_cplt is transfected without pREC_nfl_HIV-1, only the cplt-specific tag sequence is amplified from supernatants or cells.
A significant concern was maintaining the expression of HIV-1 proteins in the correct stoichiometry upon deleting the 5′ LTR. Western blots confirmed that pREC_nfl_HIV-1 produces intact HIV-1 Gag precursor protein and processed Gag p24 in the 293T cells and in the virions ( Figure 1D and Supplementary Figure 4) . These blots indicated that similar levels of Gag precursor were expressed from pREC_nfl_HIV-1 and pNL4-3 and that this precursor protein was also incorporated and processed into p24 to a similar extent in virus particles ( Figure 1D ). It is important to note that cotransfection with pCMV_cplt did not reduce virus protein levels in the 293T cells or total virus packaged in cell-free supernatants (Figure 1, D and E) . The nfl HIV-1 RNA copy number of ∼10 9 /μL is likely the maximal transcriptional level supported by the input pREC_nfl DNA transfected into the cells. A 10-fold decrease in pREC nfl DNA (0.1:1 µg pREC_nfl:pCMV_ cplt) led to an ∼8-fold decrease in nfl HIV-1 RNA ( Figure 1C) , a ∼10-fold decrease in HIV-1 p24 protein ( Figure  1D ), and reduced virus production ( Figure 1E) ; although the small amount www.invitrogen.com 30 minutes too long to wait for a gel?
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Research Reports of virus that was produced appeared infectious ( Figure 1H ). To assess virus maturation, we measured RT activity in virus particles packaged by these 293T transfections ( Figure 1E) ; RT is relatively inactive in the absence of protease processing and in immature virus particles (22) . Again, the RT levels from pREC_ nfl_HIV-1/pCMV_cplt and pNL4-3 were similar, but transfections with the lowest amount of pREC_nfl_HIV-1 (0.1 µg) showed diminished RT activity in virus particles ( Figure 1E ). This low virus production indicates that a threshold of viral structural proteins was necessary (derived from the pREC_nfl_HIV-1 vector) to yield infectious virus from the 293T packaging cell line [also shown by lack of virus produced by transfection of pCMV_cplt alone (Figure 1, C-E) ].
Testing for infectivity of virus particles with dipartite genomes Supernatants containing virus produced from 293T cells transfected with pNL4-3 or pREC_nfl_HIV-1 and +/-pCMV_cplt were used to infect U87. CD4.CXCR4 cells, a human glioma cell line used for virus propagation ( Figure  1B ). Viral RNA in the infected cells and in the cell-free supernatant was subjected to quantitative real-time RT-PCR ( Figure  1F ). Upon de novo infection of U87. CD4.CXCR4 cells with these 293T supernatants, low levels of cplt RNA were found in the U87.CD4.CXCR4 cells and supernatants and were likely the remnants of the initial virus entry rather than new RNA transcripts. The higher levels of nfl_HIV-1 genomic RNA in U87.CD4.CXCR4 cells infected with virions produced from dual transfection compared with pREC_nfl_HIV-1 alone reflects active virus replication. The low level of nfl_HIV-1 RNA found in U87. CD4.CXCR4 cells exposed to virus particles containing the nfl_HIV-1 RNA but lacking cplt RNA ( Figure 1F , first set of bars) shows that nfl_HIV-1 RNA cannot support the RT cycle in the absence of cplt RNA and is subject to RNA degradation. Based on RT activity in the supernatant, virus propagation was robust in U87.CD4.CXCR4 cells exposed to virus harboring both the nfl_HIV-1 and cplt RNA ( Figure 1H ). We could also detect precursor Gag proteins by Western blot in cells and mature Gag p24 virus in supernatant 7 days post-infection ( Figure 1G ). In contrast, cells harboring only the nfl_ HIV-1 RNA genome could not support replication ( Figure 1H , first set of bars). Production of chimeric viruses was then further optimized by selection of 293T clones stably expressing cplt RNA (293T cplt ) (Supplementary Figure 5) . Selected clones were those that supported the highest level of virus production in subsequent propagations on U87.CD4. CXCR4 cells. Virus produced from 293T cplt was more infectious (based on RT activity/mL of supernatant) than that from 293T cells transiently cotransfected with pREC_nfl_HIV-1 and pCMV_cplt (compare Figure 1E with Supplementary Figure 5) , which relates to greater expression and packaging of the cplt RNA into virus particles (data not shown). In transiently cotransfected 293T cells (1:10 ratio), cplt RNA is found at a 2-fold lower level than nfl_HIV-1 RNA in cells and at a 10-fold lower level than nfl_HIV-1 RNA in virus particles, suggesting a lower packaging efficiency of cplt RNA ( Figure 1C ). Virus produced from 293T cplt cells contain levels of cplt RNA that are only 2-fold lower than nfl RNA, resulting in a greater number of infectious particles (data not shown). Finally, consistent with the intrastrand model of reverse transcription, mutants of pCMV_cplt with a single nucleotide added to the 5′ end of the complementary RNA rendered a heterodimeric virus non-infectious (data not shown).
Application of the system to produce chimeric viruses using clinical primary isolate samples To facilitate production of chimeric viruses, conserved 40 nucleotide-long conserved sequences were identified in the flanking regions of every HIV-1 gene/coding region. One hundred to one thousand HIV-1 sequences (HIV Databases, Los Alamos National Laboratory, Los Alamos, NM, USA) from every subtype were aligned to design primers containing the conserved 40-nucleotide sequence (oligonucleotides also had a 3′ tail to amplify the yeast URA3 gene). Each gene/coding sequence in pREC_nfl_HIV-1 was then systematically replaced by URA3 using homologous recombination and by screening colonies on C-URA-LEU drop-out plates. The complete list of pREC_nfl_ HIV-1/URA3 cloning vectors is provided in Table 1 , and the binding locations of the primers used are provided in Supplementary Table 1 . To produce chimeric virus, an HIV-1 gene or coding sequence is PCR amplified from reverse-transcribed plasma RNA or cellular DNA from a patient plasma sample (or other source). The PCR product (e.g., HIV-1 env DNA) is transformed into yeast along with the appropriate pREC vector (e.g., pREC_ nfl_HIV-1Δenv/URA3) (Figure 2A) . The selection process used in this cloning system requires only minimal screening; Figure 2B highlights how the selection process eliminates incorrect clones. Yeast plated without selection grows as a lawn on YEPD plates no matter what plasmid is introduced ( Figure 2B, top panel) . C-LEU plates allow growth only when a plasmid containing the leucine gene is transformed into the yeast, such as pREC_nfl_HIV-1 or any of its derivatives. C-LEU-URA plates select for yeast containing plasmids with both leucine and URA3 genes. Lastly, C-LEU/5-FOA plates select for yeast containing a plasmid with a leucine gene, but without the URA3 gene, which creates the toxic byproduct 5-fluorouracil (5-FU) from 5-FOA ( Figure 2B , last row). In the case where a PCR product is cotransformed with a pREC_nfl_HIV-1 vector with URA3 in place of HIV-1 sequences, only successful recombination to replace the URA3 gene allows yeast to grow in the presence of 5-FOA. Yeast recombination/gap repair typically yields 100-1000 colonies on the C-LEU/5-FOA plates from an initial 3 µg of PCR product and 1 µg of plasmid (plates in Figure 2B represent colonies from a 1/100 yeast dilution).
Of patient plasma samples recombined into pREC_nflΔenv, the vast majority (315 out of 344 clones, or 92%) had the correct env insert by PCR amplication ( Figure 2C ). For samples SP8, SP11, and SP12, 96%, 85%, and 95% cloning efficiencies were observed, respectively. With sample SP11, the env PCR product was contaminated with smaller products, as detected on a 0.7% agarose gel (data not shown). These minor products likely contributed to a slightly lower cloning efficiency. Although sufficient quantities of virus were obtained from all three chimeric virus vectors (data not shown), a slight reduction in virus yield was observed with SP11 (approximately 2-fold after a 10-day propagation).
To explore in detail the use of our yeastbased cloning/virus production system for a variety of chimeric viruses, we amplified PR-RT, gag, or env genes from HIV-1 proviral DNA extracted from U87.CD4. CCR5 cells infected with subtype B primary isolates (these are known to be infectious and to efficiently replicate). PCR products were then recombined into the appropriate pREC_nfl_HIV-1/URA3 vector ( Table 1) . The plasmids were purified and then transfected into 293T cplt cells. As assessed by RT assay, significant levels of virus particles were produced by the 293T cplt cells ( Figure 3A) . This virus was propagated on U87.CD4. CXCR4 cells (gag and RT recombinants) or U87.CD4.CCR5 cells (introduction of a CCR5-tropic env) and then quantified by a standard TCID 50 assay. In just two weeks of propagation, these chimeric viruses were of substantial titers (>10 3 infectious units/mL) ( Figure 3B ). Western blots showed that the Gag proteins in these chimeric viruses had approximately the same stoichiometry as the laboratory strain, NL4-3 ( Figure 3C ). The available anti-gp120 antibodies were not cross-reactive with the Q0 and 181 env genes. However, the Q0 and 181 Env proteins were still likely to be found in the virus following 7-12 days of propagation, based on the ability of these viruses to replicate in U87. CD4.CCR5 cells ( Figure 3B ).
We also tested our system by producing chimeric viruses harboring diverse HIV-1 env genes PCR-amplified directly from plasma blood samples of infected patients. Three R5-tropic gp120 (env) genes from subtype A-infected patients (2EC, 28EC, and 38EC) were introduced into pREC_ nfl_HIV-1_Δgp120/URA3. These env genes differed from the subtype B NL4-3 by >25% in nucleotide and predicted amino-acid sequence (Figure 4, A and B Get the best from agarose gel electrophoresisvisit www.invitrogen.com/egelex and discover E-Gel® EX.
Research Reports and yet, the chimeric env viruses could be produced from 293T cplt cells ( Figure  4C ). These NL4-3/env viruses could only replicate on U87.CD4.CCR5 cells ( Figure  4E ) and not on U87.CD4.CXCR4 cells ( Figure 4D ) whereas the NL4-3 virus (i.e., the backbone of pREC_nfl_HIV-1) could only replicate on U87.CD4.CXCR4 cells, indicating correct functionality and tropism of the chimeric viruses. These three subtype A env chimeric viruses were also propagated directly from 293T supernatants in PBMC cultures of HIV-negative donors. Following propagation, the 2EC, 28EC, and 38EC reached levels of 3.5, 2.5, and 2.75 infectious units/mL ( Figure 4F ).
In all, we have successfully generated over 500 chimeric viruses harboring the env, gag, and pol genes as well as other coding sequences derived from patient samples, and these chimeras have been employed in fitness and drug susceptibility studies.
Discussion
Molecular and biochemical studies on replication or pathogenesis of HIV-1 and other RNA viruses such as hepatitis C virus are hampered by the extreme genetic diversity between different strains. Initial characterization of HIV-1 involved a select few subtype B laboratory strains, but recent studies suggest that the genetic diversity between subtypes can affect many aspects of replication (28, 29) . Furthermore, antiretroviral treatment was initially based on virus from developed countries, where subtype B infections predominate. With decreasing drug costs and treatment programs, it is now imperative to study drug resistance emerging in other HIV-1 subtypes. The use of classical bacterial cloning techniques hinder both HIV-1 mechanistic and clinical analyses due to a lack of conserved and convenient restriction enzyme sites for HIV-1 cloning. In our attempts to study the properties of non-subtype B viruses, we developed a yeast-based cloning technique to rapidly shuttle any HIV-1 gene, gene fragment, or possibly whole genome into a vector. Over 38 different genes or coding regions can now be inserted into various pREC_ nfl_HIV-1 base vectors via yeast recombination/gap repair (Table 1) . Inserts are amplified with a pair of conserved primers from any clinical sample or other source harboring HIV-1 RNA or DNA sequences representing any HIV-1 subtype. Although the cloning of an entire HIV-1 genome derived from a primary isolate source was not performed for this study, we created the pREC_nfl_HIV-1 cloning vector, which required the insertion of the entire genome (minus the 5′ LTR) of laboratory isolate pNL4-3 via two sequential yeast recombination events ( Supplementary  Figure 1) .
Because the LTR sequences at the ends of the HIV-1 genome promote rapid recombination and deletion of the HIV-1 coding regions from proviral DNA in yeast, we had to provide the RNA sequence of the LTR in trans during virus assembly. Successful virus production requires that the CMV-driven nfl_HIV-1 RNA be spliced and translated, and support virus particle production to a similar level and stoichiometry as the wild-type HIV-1 RNA genome. In addition, both the complementing RNA (cplt) and nfl_HIV-1 RNA must be expressed and packaged into assembling virus particles at similar ratios, and virus production from the packaging cell line must be robust because no more than one-half of the virus is infectious to susceptible cells. Upon infection, the short cplt RNA has to initiate reverse transcription from tRNA Lys,3 such that minus-strand strongstop DNA can jump to the nfl_HIV-1 RNA to complete reverse transcription, a process that requires cplt RNA to include the first nucleotide of the R region and the nfl_HIV-1 RNA transcription start site to be at the start of the PBS. With these elements in place, we have developed a very robust HIV-1 cloning system with significant clinical and research applications. Continued development of this system will involve improved packaging, and preliminary experiments indicate that the use of longer HIV-1 sequences in the complementing vector (pCMV_cplt) can increase RNA packaging to a level equivalent to the packaging of nfl_HIV-1 RNA (data not shown).
Looking ahead, with the advent of single-genome amplification (SGA) and parallel sequencing, our research field now has the ability to accurately sample the diversity of specific genes or entire genomes of HIV-1 as well as avoiding resampling and PCR amplification error (30) . We have recently cloned, through our yeast recombination system, full-length HIV-1 subtype C genomes derived from acute infection samples. These full-length genomes were collaboratively prepared via the Center of HIV-1/AIDS Vaccine Immunology (CHAVI) using SGA. In ongoing work, these two methodologies (yeast recombination and SGA) are being further integrated such that HIV-1 genomes of any subtype can be rapidly cloned to produce infectious virus. In attempts to extend this technology, we have recently constructed and are testing an analogous simian immunodeficiency virus (SIV) system intended for the construction of new SIV-HIV chimeric viruses (SHIVs) harboring the HIV-1 env genes of different subtypes. These SHIVenv strains will be employed in macaque pathogenesis models and for microbicide testing. Finally, this cloning technique is being employed to construct pREC_HCV vectors and to screen for new infectious HCV genomes from patients infected with all subtypes. Similar approaches are under investigation for neurominindase (NA) and hemagglutanin (HA) expression/yeast-based cloning vectors for influenza.
